Organogenesis Holdings (ORGO) Other Non-Current Liabilities (2017 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Other Non-Current Liabilities of $1.5 million for Q1 2026, up 65.66% year-over-year from $897000.0 in Q1 2025, and up 24.56% quarter-over-quarter from $1.2 million in Q4 2025.
Organogenesis Holdings (ORGO) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Organogenesis Holdings' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 65.66% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 65.66% YoY), while the FY2025 annual figure was $1.2 million, up 33.45% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.5 million, up from $1.2 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $3.0 million in Q2 2025, with the low at $894000.0 in Q4 2024.
- The 5-year median for Other Non-Current Liabilities is $1.2 million (2023), against an average of $1.4 million.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities tumbled 71.27% in 2022, then soared 138.33% in 2025.
- Organogenesis Holdings' Other Non-Current Liabilities stood at $1.1 million in 2022, then gained by 8.11% to $1.2 million in 2023, then fell by 26.3% to $894000.0 in 2024, then soared by 33.45% to $1.2 million in 2025, then rose by 24.56% to $1.5 million in 2026.
- Business Quant data shows ORGO's Other Non-Current Liabilities at $1.5 million in Q1 2026, $1.2 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Organogenesis Holdings | 240.62 Mn | 193.78 Mn | 20.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.71 Mn |
| Mar 31, 2026 | 1.49 Mn |
| Dec 31, 2025 | 1.19 Mn |
| Sep 30, 2025 | 2.51 Mn |
| Jun 30, 2025 | 3.02 Mn |
| Mar 31, 2025 | 897,000.00 |
| Dec 31, 2024 | 894,000.00 |
| Sep 30, 2024 | 1.29 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.24 Mn |
| Dec 31, 2023 | 1.21 Mn |
| Sep 30, 2023 | 1.19 Mn |
| Jun 30, 2023 | 1.19 Mn |
| Mar 31, 2023 | 1.15 Mn |
| Dec 31, 2022 | 1.12 Mn |
| Sep 30, 2022 | 1.09 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 1.56 Mn |
| Jun 30, 2021 | 927,000.00 |
| Mar 31, 2021 | 3.69 Mn |